The content on this site is intended for healthcare professionals only
Prof Robin Foa talks to ecancer at the ALL Assembly 2018 Meeting in Amsterdam about targeted treatments that are an alternative to HSCT in Ph-positive ALL.
Prof Foa outlines that we have learned that we are able treat to chronic myeloid leukaemia and Philadelphia-like ALL with tyrosine kinase inhibitors.
He understands that the evidence lacks a large randomised study, as it is a sub group of a rare disease.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.
Isatuximab with VRd can benefit newly diagnosed multiple myeloma transplant ineligible patients
Treating relapsed multiple myeloma outside of use of T-cell redirected therapies
Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies
Multiple myeloma In Rwanda: The need for further research
Addressing the rise of multiple myeloma in Rwanda
Biomarkers, predictive and prognostic factors of resistance to immunotherapy
Glofit-GemOx shows clinically meaningful benefit in relapsed/refractory diffuse large B-cell lymphoma
EHA 2024: Multiple myeloma roundup
Multiple myeloma in a resource constrained setting
